Close Menu

Palmetto

The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.

As NGS testing becomes more widespread, labs, payors, and professional groups confront questions about which genes should be required as part of clinical assays.

Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.

The organizations provided a list of genes they believe are informative in treatment of myeloid disorders and suggested several changes to the coverage policy.

Medicare contractor Palmetto is proposing to expand coverage to ensure that more patients have access to genomic profiling when tissue-based testing is not possible.

CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.

Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.

The ctDNA test will be covered for all US fee-for-service Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

Pages